Neurotech International Archives | Page 4 of 6 | Cannabiz

Company news: Neurotech; AusCann

by Steve Jones January 25, 2024July 16, 2024

Neurotech International Neurotech International (NTI) has appointed a health economic consultancy to analyse the cost benefit […]

Company news: Cann Global; Cann Group; InhaleRx; AusCann; Wellnex Life; Neurotech; MGC Pharma; Stenocare

by Martin Lane December 4, 2023April 30, 2024

Company news: Emyria; Wellnex Life; Neurotech International; Melodiol Global Health

by Martin Lane November 14, 2023April 30, 2024

Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth

by Steve Jones and Martin Lane November 1, 2023November 6, 2023

Neurotech reports positive results from latest trial of cannabinoid drug candidate NTI164

by Martin Lane October 6, 2023April 30, 2024

Company news: Vantage Hemp; Neurotech International; MediPharm Labs/Beacon Medical; Cann Group

by Martin Lane September 28, 2023April 30, 2024

Company news: Rua Bioscience; IDT Australia; Emyria; Elixinol Wellness; Neurotech; Hygrovest; Releaf Group/ICCM; Botanix

by Martin Lane August 30, 2023April 30, 2024

Roby Zomer

Company news: MGC Pharma; Neurotech International; Incannex Healthcare

by Martin Lane June 1, 2023April 30, 2024

Company news: Medicinal Harvest; Cannasouth/Eqalis; Cann Group; MGC Pharma; Incannex; Neurotech

by Martin Lane May 3, 2023April 30, 2024

Company news: Neurotech; Emyria; InhaleRx

by Martin Lane and Steve Jones March 23, 2023April 30, 2024